SDF-1 and its receptor in the ventricles of rat with monocrotaline-induced pulmonary hypertension

[1] Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cellderived factor 1 (SDF-1). J Exp Med. 1996;184(3):1101-9.10.1084/jem.184.3.110121927989064327Search in Google Scholar

[2] Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135(3):794-804.10.1378/chest.08-049219265089Search in Google Scholar

[3] Burke DL, Frid MG, Kunrath CL et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol. 2009;297(2):L238-50.10.1152/ajplung.90591.2008274280019465514Search in Google Scholar

[4] Doka G, Malikova E, Galkova K et al. Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy. Mol Cell Biochem. 2017;432(1-2):79-89.10.1007/s11010-017-2999-828303410Search in Google Scholar

[5] Gambaryan N, Perros F, Montani D et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J. 2011;37(6):1392-9.10.1183/09031936.0004571020884740Search in Google Scholar

[6] Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016;69(2):177.10.1016/j.recesp.2016.01.002Search in Google Scholar

[7] Gomez-Arroyo JG, Farkas L, Alhussaini AA et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012;302(4):L363-9.10.1152/ajplung.00212.201121964406Search in Google Scholar

[8] Hoeper MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42-50.10.1016/j.jacc.2013.10.03224355641Search in Google Scholar

[9] Jackson EK, Zhang Y, Gillespie DD, Zhu X, Cheng D, Jackson TC. SDF-1α (Stromal Cell-Derived Factor 1α) Induces Cardiac Fibroblasts, Renal Microvascular Smooth Muscle Cells, and Glomerular Mesangial Cells to Proliferate, Cause Hypertrophy, and Produce Collagen. J Am Heart Assoc. 2017;6(11).10.1161/JAHA.117.007253572179429114002Search in Google Scholar

[10] Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115-30.10.1161/CIRCRESAHA.115.301146409668624951762Search in Google Scholar

[11] McCullagh BN, Costello CM, Li L et al. Elevated plasma CXCL12α is associated with a poorer prognosis in pulmonary arterial hypertension. PLoS One. 2015;10(4):e0123709.10.1371/journal.pone.0123709439183325856504Search in Google Scholar

[12] Schioppa T, Uranchimeg B, Saccani A et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med. 2003;198(9):1391-402.10.1084/jem.20030267219424814597738Search in Google Scholar

[13] Shao S, Cai W, Sheng J, Yin L. Role of SDF-1 and Wnt signaling pathway in the myocardial fibrosis of hypertensive rats. Am J Transl Res. 2015;7(8):1345-56.Search in Google Scholar

[14] Srankova J, Doka G, Pivackova L et al. Daunorubicin Down-Regulates the Expression of Stem Cell Markers and Factors Involved in Stem Cell Migration and Homing in Rat Heart in Subchronic but not Acute Cardiomyopathy. Basic Clin Pharmacol Toxicol. 2016;119(5):443-452.10.1111/bcpt.1260627090888Search in Google Scholar

[15] Sutendra G, Dromparis P, Paulin R et al. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl). 2013;91(11):1315-27.10.1007/s00109-013-1059-423846254Search in Google Scholar

[16] Yu L, Hales CA. Effect of chemokine receptor CXCR4 on hypoxiainduced pulmonary hypertension and vascular remodeling in rats. Respir Res. 2011;12:21.10.1186/1465-9921-12-21304239821294880Search in Google Scholar

[17] Wang ER, Jarrah AA, Benard L et al. Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administration. Gene Ther. 2014;21(5):496-506.10.1038/gt.2014.23401611224646609Search in Google Scholar